Previous research by our group and others has demonstrated that AD patients have mildly elevated levels of plasma cortisol, that approximately 40-50% of patients do not suppress cortisol secretion normally following dexamethasone administration, and that some AD patients have blunted cortisol responses to challenges with either TRH or CRF. These abnormalities are generally correlated with the extent of behavioral impairment. Numerous animal studies indicate that chronic elevation of corticosteroids may lead to neuron loss particularly in the hippocampus and that damage to the hippocampus, in turn, can lead to disinhibition of the HPA axis. We propose to determine whether any of the observed HPA axis abnormalities observed in AD patients are related to clinically significant differences in symptom progression over time, and whether HPA axis abnormalities are associated with the loss of neurotransmitter markers or cells in the hippocampus of patients who come to autopsy. During the next five years we will collect baseline HPA axis data, perform dexamethasone suppression tests, and give CRF infusions to at least 40 mild to moderately demented AD patients at baseline and yearly for at least 2 years. Changes in HPA axis measures will be correlated with changes in AD symptomatology measured by the Alzheimer's Disease Assessment Scale. In addition we will perform these same HPA axis tests on a group of at least 30 AD patients with advanced disease who are residing in extended care facilities with high autopsy rates. Autopsies will be performed on patients in either group who die during the next five years to determine loss of neurotransmitter markers and hippocampal cells.

National Institute of Health (NIH)
National Institute on Aging (NIA)
Specialized Center (P50)
Project #
Application #
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mount Sinai School of Medicine
New York
United States
Zip Code
Agrawal, A; Chou, Y-L; Carey, C E et al. (2018) Genome-wide association study identifies a novel locus for cannabis dependence. Mol Psychiatry 23:1293-1302
Brenowitz, Willa D; Han, Fang; Kukull, Walter A et al. (2018) Treated hypothyroidism is associated with cerebrovascular disease but not Alzheimer's disease pathology in older adults. Neurobiol Aging 62:64-71
Dobbyn, Amanda; Huckins, Laura M; Boocock, James et al. (2018) Landscape of Conditional eQTL in Dorsolateral Prefrontal Cortex and Co-localization with Schizophrenia GWAS. Am J Hum Genet 102:1169-1184
Cruchaga, Carlos; Del-Aguila, Jorge L; Saef, Benjamin et al. (2018) Polygenic risk score of sporadic late-onset Alzheimer's disease reveals a shared architecture with the familial and early-onset forms. Alzheimers Dement 14:205-214
Alosco, Michael L; Sugarman, Michael A; Besser, Lilah M et al. (2018) A Clinicopathological Investigation of White Matter Hyperintensities and Alzheimer's Disease Neuropathology. J Alzheimers Dis 63:1347-1360
Kinnunen, Kirsi M; Cash, David M; Poole, Teresa et al. (2018) Presymptomatic atrophy in autosomal dominant Alzheimer's disease: A serial magnetic resonance imaging study. Alzheimers Dement 14:43-53
Brent, Robert J (2018) Estimating the monetary benefits of medicare eligibility for reducing the symptoms of dementia. Appl Econ 50:6327-6340
Moreno, Cesar L; Della Guardia, Lucio; Shnyder, Valeria et al. (2018) iPSC-derived familial Alzheimer's PSEN2 N141I cholinergic neurons exhibit mutation-dependent molecular pathology corrected by insulin signaling. Mol Neurodegener 13:33
Deming, Yuetiva; Dumitrescu, Logan; Barnes, Lisa L et al. (2018) Sex-specific genetic predictors of Alzheimer's disease biomarkers. Acta Neuropathol 136:857-872
Gallagher, Damien; Kiss, Alex; Lanctot, Krista L et al. (2018) Toward Prevention of Mild Cognitive Impairment in Older Adults With Depression: An Observational Study of Potentially Modifiable Risk Factors. J Clin Psychiatry 80:

Showing the most recent 10 out of 555 publications